Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9943993 | 0.87 | GSK3B (0.49) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL697113 | 0.84 | GSK3B (0.55) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL696621 | 0.84 | GSK3B (0.55) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL697682 | 0.84 | GSK3B (0.55) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL698483 | 0.83 | GSK3B (0.58) | GSK3BCYP1A2CYP2D6CSNK1A1GSK3A | |
| SCHEMBL696677 | 0.83 | GSK3B (0.58) | GSK3BCYP1A2CYP2D6CSNK1A1GSK3A | |
| SCHEMBL696844 | 0.83 | GSK3B (0.58) | GSK3BCYP1A2CYP2D6CSNK1A1GSK3A | |
| SCHEMBL8232562 | 0.76 | GSK3B (0.55) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL697778 | 0.76 | GSK3B (0.55) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL8232479 | 0.75 | GSK3B (0.54) | GSK3BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | claimed |
| US-8940738-B2 | Pyrimidone compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940738-B2 | Pyrimidone compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940738-B2 | Pyrimidone compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | disclosed |
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | disclosed |
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | disclosed |
| EP-2464639-A1 | PYRIMIDONE DERIVATIVES USED AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | MAPT, PRNP, PSEN1 | GSK3B 310/4885CYP1A2 2029/4885CYP2D6 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.